Abstract
Cancer
nanovaccines
represent
a
promising
frontier
in
cancer
immunotherapy,
utilizing
nanotechnology
to
augment
traditional
vaccine
efficacy.
This
review
comprehensively
examines
the
current
state‐of‐the‐art
nanovaccine
development,
elucidating
innovative
strategies
and
technologies
employed
their
design.
It
explores
both
preclinical
clinical
advancements,
emphasizing
key
studies
demonstrating
potential
elicit
robust
anti‐tumor
immune
responses.
The
study
encompasses
various
facets,
including
integrating
biomaterial‐based
nanocarriers
for
antigen
delivery,
adjuvant
selection,
impact
of
nanoscale
properties
on
performance.
Detailed
insights
into
complex
interplay
between
tumor
microenvironment
responses
are
provided,
highlighting
challenges
opportunities
optimizing
therapeutic
outcomes.
Additionally,
presents
thorough
analysis
ongoing
trials,
presenting
snapshot
landscape.
By
curating
latest
scientific
findings
developments,
this
aims
serve
as
comprehensive
resource
researchers
clinicians
engaged
advancing
immunotherapy.
Integrating
design
holds
immense
promise
revolutionizing
treatment
paradigms,
provides
timely
update
evolving
landscape
nanovaccines.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(3), С. 2700 - 2700
Опубликована: Янв. 31, 2023
mRNA
vaccines
have
been
demonstrated
as
a
powerful
alternative
to
traditional
conventional
because
of
their
high
potency,
safety
and
efficacy,
capacity
for
rapid
clinical
development,
potential
rapid,
low-cost
manufacturing.
These
progressed
from
being
mere
curiosity
emerging
COVID-19
pandemic
vaccine
front-runners.
The
advancements
in
the
field
nanotechnology
developing
delivery
vehicles
are
highly
significant.
In
this
review
we
summarized
each
every
aspect
vaccine.
article
describes
structure,
its
pharmacological
function
immunity
induction,
lipid
nanoparticles
(LNPs),
upstream,
downstream,
formulation
process
Additionally,
trials
also
described.
A
deep
dive
into
future
perspectives
vaccines,
such
freeze-drying,
systems,
LNPs
targeting
antigen-presenting
cells
dendritic
cells,
summarized.
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Фев. 21, 2024
Abstract
Inflammation-associated
diseases
encompass
a
range
of
infectious
and
non-infectious
inflammatory
diseases,
which
continuously
pose
one
the
most
serious
threats
to
human
health,
attributed
factors
such
as
emergence
new
pathogens,
increasing
drug
resistance,
changes
in
living
environments
lifestyles,
aging
population.
Despite
rapid
advancements
mechanistic
research
development
for
these
current
treatments
often
have
limited
efficacy
notable
side
effects,
necessitating
more
effective
targeted
anti-inflammatory
therapies.
In
recent
years,
nanotechnology
has
provided
crucial
technological
support
prevention,
treatment,
detection
inflammation-associated
diseases.
Various
types
nanoparticles
(NPs)
play
significant
roles,
serving
vaccine
vehicles
enhance
immunogenicity
carriers
improve
targeting
bioavailability.
NPs
can
also
directly
combat
pathogens
inflammation.
addition,
facilitated
biosensors
pathogen
imaging
techniques
This
review
categorizes
characterizes
different
NPs,
summarizes
their
applications
It
discusses
challenges
associated
with
clinical
translation
this
field
explores
latest
developments
prospects.
conclusion,
opens
up
possibilities
comprehensive
management
Bioconjugate Chemistry,
Год журнала:
2023,
Номер
34(6), С. 941 - 960
Опубликована: Май 10, 2023
Lipid
nanoparticles
(LNPs)
have
been
recognized
as
efficient
vehicles
to
transport
a
large
variety
of
therapeutics.
Currently
in
the
spotlight
important
constituents
COVID-19
mRNA
vaccines,
LNPs
play
significant
role
protecting
and
transporting
cells.
As
one
their
key
constituents,
polyethylene
glycol
(PEG)–lipid
conjugates
are
defining
LNP
physicochemical
characteristics
biological
activity.
PEGylation
has
proven
particularly
conferring
longer
systemic
circulation
LNPs,
thus
greatly
improving
pharmacokinetics
efficiency.
Along
with
revealing
benefits
PEG
conjugates,
studies
revealed
unexpected
immune
reactions
against
PEGylated
nanocarriers
such
accelerated
blood
clearance
(ABC),
involving
production
anti-PEG
antibodies
at
initial
injection,
which
initiates
upon
subsequent
injections,
well
hypersensitivity
reaction
referred
complement
activation-related
pseudoallergy
(CARPA).
Further,
data
accumulated
indicating
consistent
yet
sometimes
controversial
correlations
between
various
structural
parameters
PEG–lipids,
properties
magnitude
observed
adverse
effects.
Detailed
knowledge
comprehension
foremost
importance
efforts
diminish
eliminate
undesirable
improve
safety
efficiency
medicines.
Here,
we
present
an
overview
based
on
analysis
from
CAS
Content
Collection
regarding
immunogenicity
overall
concerns.
A
comprehensive
summary
compiled
outlining
how
PEG–lipids
affect
responses
activities
regards
drug
delivery.
This
Review
is
intended
serve
helpful
resource
understanding
current
field,
effort
further
solve
remaining
challenges
achieve
full
potential.
Acta Pharmaceutica Sinica B,
Год журнала:
2023,
Номер
13(11), С. 4391 - 4416
Опубликована: Май 20, 2023
Owing
to
the
inherent
shortcomings
of
traditional
therapeutic
drugs
in
terms
inadequate
efficacy
and
toxicity
clinical
treatment,
nanomedicine
designs
have
received
widespread
attention
with
significantly
improved
reduced
non-target
side
effects.
Nanomedicines
hold
tremendous
theranostic
potential
for
treating,
monitoring,
diagnosing,
controlling
various
diseases
are
attracting
an
unfathomable
amount
input
research
resources.
Against
backdrop
exponentially
growing
number
publications,
it
is
imperative
help
audience
get
a
panorama
image
activities
field
nanomedicines.
Herein,
this
review
elaborates
on
development
trends
nanomedicines,
emerging
nanocarriers,
vivo
fate
safety
their
extensive
applications.
Moreover,
challenges
obstacles
hindering
translation
nanomedicines
also
discussed.
The
elaboration
aspects
may
enlighten
readers
set
route
future
endeavors.
Journal of Biomedical Science,
Год журнала:
2023,
Номер
30(1)
Опубликована: Окт. 7, 2023
mRNA-based
drugs
have
tremendous
potential
as
clinical
treatments,
however,
a
major
challenge
in
realizing
this
drug
class
will
promise
to
develop
methods
for
safely
delivering
the
bioactive
agents
with
high
efficiency
and
without
activating
immune
system.
With
regard
mRNA
vaccines,
researchers
modified
structure
enhance
its
stability
promote
systemic
tolerance
of
antigenic
presentation
non-inflammatory
contexts.
Still,
delivery
naked
mRNAs
is
inefficient
results
low
levels
antigen
protein
production.
As
such,
lipid
nanoparticles
been
utilized
improve
protect
cargo
from
extracellular
degradation.
This
advance
was
milestone
development
vaccines
dispelled
skepticism
about
technology
yield
clinically
approved
medicines.
Following
resounding
success
COVID-19,
many
other
proposed
treatment
variety
diseases.
review
begins
discussion
modifications
vehicles,
well
factors
that
influence
administration
routes.
Then,
we
summarize
applications
discuss
further
key
points
pertaining
preclinical
targeting
wide
range
Finally,
latest
market
trends
future
drugs.
Advanced Materials,
Год журнала:
2023,
Номер
36(4)
Опубликована: Авг. 7, 2023
Abstract
Lipid
nanoparticles
(LNPs)
are
currently
the
most
promising
clinical
nucleic
acids
drug
delivery
vehicles.
LNPs
prevent
degradation
of
cargo
during
blood
circulation.
Upon
entry
into
cell,
specific
components
lipid
can
promote
endosomal
escape
acids.
These
basic
properties
as
acid
carriers.
As
exhibit
hepatic
aggregation
characteristics,
enhancing
targeting
out
liver
is
a
crucial
way
to
improve
administrated
in
vivo.
Meanwhile,
loaded
often
considered
inadequate,
and
therefore,
much
effort
devoted
intracellular
release
efficiency
Here,
different
strategies
efficiently
deliver
from
concluded
their
mechanisms
investigated.
In
addition,
based
on
information
that
trials
or
have
completed
trials,
issues
necessary
be
approached
translation
discussed,
which
it
hoped
will
shed
light
development
LNP
drugs.
Advanced Materials,
Год журнала:
2023,
Номер
unknown
Опубликована: Окт. 4, 2023
Abstract
Lipid‐based
nanoparticles
(LBNPs)
are
currently
the
most
promising
vehicles
for
nucleic
acid
drug
(NAD)
delivery.
Although
their
clinical
applications
have
achieved
success,
NAD
delivery
efficiency
and
safety
still
unsatisfactory,
which
are,
to
a
large
extent,
due
existence
of
multi‐level
physiological
barriers
in
vivo.
It
is
important
elucidate
interactions
between
these
LBNPs,
will
guide
more
rational
design
efficient
with
low
adverse
effects
facilitate
broader
therapeutics.
This
review
describes
obstacles
challenges
biological
at
systemic,
organ,
sub‐organ,
cellular,
subcellular
levels.
The
strategies
overcome
comprehensively
reviewed,
mainly
including
physically/chemically
engineering
LBNPs
directly
modifying
by
auxiliary
treatments.
Then
potentials
successful
translation
preclinical
studies
into
clinic
discussed.
In
end,
forward
look
on
manipulating
protein
corona
(PC)
addressed,
may
pull
off
trick
overcoming
those
significantly
improve
efficacy
LBNP‐based
NADs
